Literature DB >> 2039823

Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia.

B D Nelkin1, D Przepiorka, P J Burke, E D Thomas, S B Baylin.   

Abstract

The clinical aspects of disease progression in chronic myelogenous leukemia (CML) are well established, but the nature of the molecular events responsible is not known. We have previously reported a consistent pattern of novel sites of methylation in the 5' region of the calcitonin (CT) gene and other chromosome 11p loci in acute myelogenous and and lymphoid leukemias. In the present study, CT gene methylation patterns were investigated in peripheral blood from 51 patients with CML. Abnormal patterns were found in only 2 of 31 patients in chronic phase, but in 5 of 8 patients in accelerated phase, and in 11 of 12 patients in blast crisis (P less than .005). For one patient studied in blast crisis, abnormal CT gene methylation was found in the peripheral blast cells but not in the granulocytes. In two of three patients studied with CML and having normal peripheral cell patterns, abnormal patterns were found in marrow blast cells. In one patient, only partial normalization of the CT gene methylation pattern was seen after chemotherapy induction of a second chronic phase and the patient relapsed 5 months later. Our findings indicate that abnormal methylation of the 5' region of the CT gene is regularly a marker of disease progression in CML which may prove clinically useful. This abnormal methylation site is part of an imbalance in DNA methylation that may play a role in the progressive genetic instability which characterizes the advancing stages of CML.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039823

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Myelodysplastic syndromes.

Authors:  I M Hann
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

2.  Concurrent replication and methylation at mammalian origins of replication.

Authors:  F D Araujo; J D Knox; M Szyf; G B Price; M Zannis-Hadjopoulos
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

3.  Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide.

Authors:  S Ramchandani; A R MacLeod; M Pinard; E von Hofe; M Szyf
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 4.  Methylation matters.

Authors:  J F Costello; C Plass
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

5.  Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.

Authors:  M Zion; D Ben-Yehuda; A Avraham; O Cohen; M Wetzler; D Melloul; Y Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

6.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Authors:  J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

7.  Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain.

Authors:  T H Bestor
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

Review 8.  Role of epigenetics in chronic myeloid leukemia.

Authors:  Katerina Machova Polakova; Jitka Koblihova; Tomas Stopka
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

9.  Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.

Authors:  Jaroslav Jelinek; Vazganush Gharibyan; Marcos R H Estecio; Kimie Kondo; Rong He; Woonbok Chung; Yue Lu; Nianxiang Zhang; Shoudan Liang; Hagop M Kantarjian; Jorge E Cortes; Jean-Pierre J Issa
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

10.  Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.

Authors:  Sameer Ahmad Guru; Mamta Pervin Sumi; Rashid Mir; Mirza Masroor Ali Beg; Bidhan Chandra Koner; Alpana Saxena
Journal:  BMC Cancer       Date:  2022-04-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.